Literature DB >> 15460963

Age-related risk of adverse events following yellow fever vaccination in Australia.

Glenda L Lawrence1, Margaret A Burgess, Robert B Kass.   

Abstract

Reports of six deaths internationally, including one from Australia, plus other cases of severe systemic adverse events following yellow fever (YF) vaccination have raised concern about the safety of YF vaccine, particularly among older vaccinees. We investigated the age-related reporting rates of adverse events following YF vaccination reported to the Australian Adverse Drug Reactions Advisory Committee for the period 1993 to 2002. The reporting rate of systemic adverse events leading to hospitalisation or death was significantly higher among vaccinees aged > or = 65 years [reporting rate ratio (RRR) 8.95, 95% confidence interval (CI) 1.49-53.5] or > or = 45 years (RRR 5.30, 95% CI 1.33-21.2) compared with younger YF vaccinees. The higher reporting rates among older vaccinees are similar to those identified in the United States of America. The data highlight the importance of assessing the destination-specific risk, especially for older travellers to yellow fever endemic areas, and careful monitoring of those who are vaccinated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15460963

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  11 in total

Review 1.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

3.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

Review 4.  Vaccines and Senior Travellers.

Authors:  Fiona Ecarnot; Stefania Maggi; Jean-Pierre Michel; Nicola Veronese; Andrea Rossanese
Journal:  Front Aging       Date:  2021-07-09

5.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

6.  Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model.

Authors:  Flora Engelmann; Laurence Josset; Thomas Girke; Byung Park; Alex Barron; Jesse Dewane; Erika Hammarlund; Anne Lewis; Michael K Axthelm; Mark K Slifka; Ilhem Messaoudi
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

Review 7.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

Review 8.  Yellow fever vaccine and risk of developing serious adverse events: a systematic review.

Authors:  Ruben Porudominsky; Eduardo H Gotuzzo
Journal:  Rev Panam Salud Publica       Date:  2018-06-05

Review 9.  Vaccinology in the third millennium: scientific and social challenges.

Authors:  Gregory A Poland; Jennifer A Whitaker; Caroline M Poland; Inna G Ovsyannikova; Richard B Kennedy
Journal:  Curr Opin Virol       Date:  2016-03-30       Impact factor: 7.090

Review 10.  A clinician's perspective on yellow fever vaccine-associated neurotropic disease.

Authors:  Elien Lecomte; Guy Laureys; Frederick Verbeke; Cristina Domingo Carrasco; Marjan Van Esbroeck; Ralph Huits
Journal:  J Travel Med       Date:  2020-11-09       Impact factor: 8.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.